Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 11, 2015, Pages E1272-E1277

  Kannan, Kalpana ^a   Coarfa, Cristian ^a   Chao, Pei Wen ^a   Luo, Liming ^a   Wang, Yan ^a   Brinegar, Amy E ^a   Hawkins, Shannon M ^a   Milosavljevic, Aleksandar ^a   Matzuk, Martin M ^a   Yen, Laising ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

AKT2; BCAM; Cancer specific fusion gene; Fusion kinase; High grade serous ovarian cancer

Indexed keywords

BCAM PROTEIN; HYBRID PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B BETA; SOMATOMEDIN C; UNCLASSIFIED DRUG; AKT2 PROTEIN, HUMAN; BCAM-AKT2 FUSION PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN; PROTEIN KINASE B;

ARTICLE; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION; CRISPR CAS SYSTEM; ENZYME ACTIVATION; ENZYME MECHANISM; FUSION GENE; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENE TARGETING; HEK293 CELL LINE; HIGH GRADE SEROUS OVARIAN CARCINOMA; HUMAN; HUMAN TISSUE; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; AMINO ACID SEQUENCE; CANCER GRADING; CELL MEMBRANE; CHEMISTRY; CYSTADENOCARCINOMA; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC TRANSFECTION; GENETICS; HUMAN CHROMOSOME; METABOLISM; MOLECULAR GENETICS; NEOPLASM; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; PROTEIN SYNTHESIS; TUMOR CELL LINE;

AMINO ACID SEQUENCE; BASE SEQUENCE; CELL LINE, TUMOR; CELL MEMBRANE; CHROMOSOMES, HUMAN; CRISPR-CAS SYSTEMS; CYSTADENOCARCINOMA, SEROUS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM GRADING; NEOPLASMS, GLANDULAR AND EPITHELIAL; ONCOGENE PROTEINS, FUSION; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TRANSFECTION; TRANSLOCATION, GENETIC;

EID: 84925340715     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1501735112     Document Type: Article

References (33)

1. Jemal A, et al. (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90.
2. Bell D, et al.; Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609-615.
3. Bast RC, Jr, Mills GB (2012) Dissecting "PI3Kness": The complexity of personalized therapy for ovarian cancer. Cancer Discov 2(1):16-18.
4. Mitelman F, Johansson B, Mertens F (2007) The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7(4):233-245.
5. Tomlins SA, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644-648.
6. Singh D, et al. (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337(6099):1231-1235.
7. Honeyman JN, et al. (2014) Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343(6174):1010-1014.
8. Romero I, Bast RC, Jr (2012) Minireview: Human ovarian cancer: Biology, current management, and paths to personalizing therapy. Endocrinology 153(4):1593-1602.
9. Garofalo RS, et al. (2003) Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 112(2):197-208.
10. Hers I, Vincent EE, Tavaré JM (2011) Akt signalling in health and disease. Cell Signal 23(10):1515-1527.
11. Bellacosa A, et al. (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64(4):280-285.
12. Cheng JQ, et al. (1992) AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89(19):9267-9271.
13. Altomare DA, et al. (2004) AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23(34):5853-5857.
14. Yuan ZQ, et al. (2000) Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19(19):2324-2330.
15. Kannan K, et al. (2014) CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma. PLoS Genet 10(3):e1004216.
16. Kim P, et al. (2010) ChimerDB 2.0 - A knowledgebase for fusion genes updated. Nucleic Acids Res 38(Database issue):D81-D85.
17. McPherson A, et al. (2011) deFuse: An algorithm for gene fusion discovery in tumor RNA-seq data. PLOS Comput Biol 7(5):e1001138.
18. Salzman J, et al. (2011) ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma. PLoS Biol 9(9):e1001156.
19. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C (2014) The landscape of kinase fusions in cancer. Nat Commun 5:4846.
20. Lieber MR (2010) The mechanism of double-strand DNA break repair by the non-homologous DNA end-joining pathway. Annu Rev Biochem 79:181-211.
21. Zhang F, Carvalho CM, Lupski JR (2009) Complex human chromosomal and genomic rearrangements. Trends Genet 25(7):298-307.
22. El Nemer W, et al. (1999) Isoforms of the Lutheran/basal cell adhesion molecule glycoprotein are differentially delivered in polarized epithelial cells. Mapping of the basolateral sorting signal to a cytoplasmic di-leucine motif. J Biol Chem 274(45):31903-31908.
23. Garinchesa P, Sanzmoncasi M, Campbell I, Rettig W (1994) Non-polarized expression of basal-cell adhesion molecule B-CAM in epithelial ovarian cancers. Int J Oncol 5(6):1261-1266.
24. Franke TF, et al. (1995) The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81(5):727-736.
25. Liu AX, et al. (1998) AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res 58(14):2973-2977.
26. Watton SJ, Downward J (1999) Akt/PKB localisation and 3' phosphoinositide generation at sites of epithelial cell-matrix and cell-cell interaction. Curr Biol 9(8):433-436.
27. Torres R, et al. (2014) Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. Nat Commun 5:3964.
28. Micci F, et al. (2014) Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas. PLoS Biol 12(2):e1001784.
29. Andjelković M, et al. (1997) Role of translocation in the activation and function of protein kinase B. J Biol Chem 272(50):31515-31524.
30. Meier R, Alessi DR, Cron P, Andjelković M, Hemmings BA (1997) Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bbeta. J Biol Chem 272(48):30491-30497.
31. Mende I, Malstrom S, Tsichlis PN, Vogt PK, Aoki M (2001) Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 20(32):4419-4423.
32. Carpten JD, et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152):439-444.
33. Banerji S, et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486(7403):405-409.